Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about P2RX7: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
P2RX7 is a gene implicated in neurodegeneration research. Key relationships include: regulates, associated with, activates. Associated with ALS, Aging, Als. Connected to 135 entities in the SciDEX knowledge graph.
No AI portrait yet
| Gene Symbol | P2RX7 |
| Full Name | Purinergic Receptor P2X Ligand-Gated Ion Channel 7 |
| Chromosome | 12 |
| Protein Type | Ion Channel |
| Target Class | Ion Channel |
| Function | Selective P2X7 receptor antagonists blocking ATP-gated ion channel |
| Mechanism of Action | Selective P2X7 receptor antagonists blocking ATP-gated ion channel |
| Druggability | High (0.80) |
| Clinical Stage | Phase II |
| Molecular Weight | 68.6 kDa |
| Amino Acids | 595 aa |
| Pathways | Glucose Metabolism, Lipid Metabolism, Phagocytosis, tau accumulation, tau propagation |
| UniProt ID | Q99572 |
| NCBI Gene ID | 10278 |
| Ensembl ID | ENSG00000088038 |
| OMIM | 601636 |
| GeneCards | P2RX7 |
| Human Protein Atlas | P2RX7 |
| Associated Diseases | Als, Alzheimer, Alzheimer's disease |
| Known Drugs/Compounds | therapeutic_target |
| Interactions | ACHE, AD, adora2b, ADORA2B, Alpha-Synuclein, ALPHA-SYNUCLEIN |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | P2RX7-Mediated Exosome Secretion Blockade |
| KG Connections | 638 knowledge graph edges |
| Databases | GeneCardsHPASTRING |
Knowledge base pages for this entity
graph TD
P2RX7["P2RX7"] -->|"associated"| neurodegeneration["neurodegeneration"]
P2RX7["P2RX7"] -->|"interacts"| P2RY1["P2RY1"]
P2RX7["P2RX7"] -->|"co discussed"| DGAT1["DGAT1"]
P2RX7["P2RX7"] -->|"co discussed"| C3["C3"]
P2RX7["P2RX7"] -->|"co discussed"| AQP4["AQP4"]
P2RX7["P2RX7"] -->|"co discussed"| EPHB4["EPHB4"]
P2RY1_1["P2RY1"] -->|"interacts"| P2RX7["P2RX7"]
BMAL1["BMAL1"] -->|"co discussed"| P2RX7["P2RX7"]
HK2["HK2"] -->|"co discussed"| P2RX7["P2RX7"]
MIRO1["MIRO1"] -->|"co discussed"| P2RX7["P2RX7"]
style P2RX7 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0| Target | Relation | Type | Str |
|---|---|---|---|
| LUNG TISSUE | expressed_in | entity | 0.95 |
| UPREGULATES | upregulates | entity | 0.95 |
| Extracellular Vesicles | regulates | mechanism | 0.95 |
| Glucose Homeostasis | regulates | phenotype | 0.93 |
| PANCREATIC B-CELLS | expressed_in | entity | 0.90 |
| extracellular nucleotide signaling | involved_in | pathway | 0.90 |
| purinergic signaling | involved_in | pathway | 0.90 |
| GLUCOSE HOMEOSTASIS | regulates | entity | 0.90 |
| Brain Atrophy | contributes_to | phenotype | 0.90 |
| Neurodegeneration | contributes_to | process | 0.90 |
| THERAPEUTIC_TARGET | therapeutic_target | entity | 0.90 |
| IMMUNE CELLS | expressed_in | entity | 0.90 |
| pancreatic beta cells | expressed_in | cell_type | 0.88 |
| COVID-19 | upregulates | disease | 0.85 |
| Glucose Homeostasis | associated_with | process | 0.85 |
| Diabetes | risk_factor_for | disease | 0.85 |
| Lung Tissue | expressed_in | cell_type | 0.85 |
| Glycemic Traits | associated_with | phenotype | 0.80 |
| neurons | expressed_in | cell_type | 0.80 |
| Glucose Metabolism | regulates | pathway | 0.80 |
| Type 2 Diabetes Mellitus | associated_with | disease | 0.75 |
| Type 2 Diabetes | associated_with | disease | 0.75 |
| STING | activates | gene | 0.70 |
| STING | causes | gene | 0.70 |
| VEGF | activates | gene | 0.70 |
| P2RY12 | inhibits | gene | 0.70 |
| P2RY1 | interacts_with | gene | 0.66 |
| neurodegeneration | associated_with | disease | 0.66 |
| Alzheimer | associated_with | disease | 0.65 |
| Als | associated_with | disease | 0.65 |
| Dementia | expressed_in | disease | 0.65 |
| Anxiety | inhibits | disease | 0.65 |
| TAU | inhibits | gene | 0.65 |
| TAU | mediates | gene | 0.65 |
| TAU | impairs | gene | 0.65 |
| exosome_secretion | regulates | pathway | 0.65 |
| Covid | activates | disease | 0.65 |
| Autoimmune | associated_with | disease | 0.65 |
| Inflammation | expressed_in | disease | 0.65 |
| ALS | regulates | disease | 0.65 |
| Als | causes | disease | 0.65 |
| Neurodegeneration | expressed_in | disease | 0.65 |
| Als | inhibits | disease | 0.65 |
| Inflammation | regulates | disease | 0.65 |
| Aging | activates | disease | 0.65 |
| Tauopathy | regulates | disease | 0.65 |
| Parkinson | interacts_with | disease | 0.65 |
| Alzheimer | regulates | disease | 0.65 |
| Multiple Sclerosis | expressed_in | disease | 0.65 |
| Depression | associated_with | disease | 0.65 |
| Source | Relation | Type | Str |
|---|---|---|---|
| PMID_31187411 | no_GWAS_AD_association | publication | 0.00 |
| H3 | antagonizes | hypothesis | 0.00 |
| h-1333080b | targets_gene | hypothesis | 0.90 |
| h-0758b337 | targets | hypothesis | 0.80 |
| NLRP3 | expressed_in | gene | 0.70 |
| CCL2 | expresses | gene | 0.70 |
| OLIGODENDROCYTE | expresses | cell_type | 0.70 |
| OLIGODENDROCYTES | expresses | cell_type | 0.70 |
| OLIGODENDROCYTES | inhibits | cell_type | 0.70 |
| OLIGODENDROCYTE | inhibits | cell_type | 0.70 |
| MICROGLIA | expressed_in | cell_type | 0.70 |
| ASTROCYTE | expresses | cell_type | 0.70 |
| ENDOTHELIAL | activates | cell_type | 0.70 |
| HSP90 | activates | gene | 0.70 |
| HSP90 | expresses | gene | 0.70 |
| ACHE | activates | gene | 0.70 |
| NEURONS | inhibits | cell_type | 0.70 |
| GPX4 | activates | gene | 0.70 |
| P2RY1 | interacts_with | gene | 0.66 |
| EPILEPSY | associated_with | disease | 0.65 |
| IL18 | inhibits | gene | 0.65 |
| P2X7 | inhibits | gene | 0.65 |
| ATP | inhibits | gene | 0.65 |
| ENTORHINAL CORTEX | inhibits | brain_region | 0.65 |
| ATP | transports | gene | 0.60 |
| EGFR | contributes_to | gene | 0.60 |
| IL-1 | activates | gene | 0.60 |
| HMOX1 | contributes_to | gene | 0.60 |
| APP | expressed_in | gene | 0.60 |
| TAUOPATHY | regulates | gene | 0.60 |
| SERPINE1 | contributes_to | gene | 0.60 |
| HSP90AA1 | expressed_in | gene | 0.60 |
| SLC17A9 | associated_with | gene | 0.60 |
| CX3CR1 | associated_with | gene | 0.60 |
| SNCA | interacts_with | gene | 0.60 |
| SCN10A | associated_with | gene | 0.60 |
| INPP4A | associated_with | gene | 0.60 |
| EGFR | biomarker_for | gene | 0.60 |
| HMOX1 | biomarker_for | gene | 0.60 |
| IGF1 | biomarker_for | gene | 0.60 |
| HSP90AA1 | associated_with | gene | 0.60 |
| NT5E | associated_with | gene | 0.60 |
| IL18 | regulates | gene | 0.60 |
| ASTROCYTE | inhibits | cell_type | 0.60 |
| CA1 | inhibits | brain_region | 0.60 |
| CORTEX | inhibits | brain_region | 0.60 |
| ENTORHINAL | inhibits | brain_region | 0.60 |
| HIPPOCAMPUS | inhibits | brain_region | 0.60 |
| MICROGLIA | causes | cell_type | 0.60 |
| NEURON | expressed_in | cell_type | 0.60 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| P2RX7-Mediated Exosome Secretion Blockade | 0.552 | neurodegeneration | Tau propagation mechanisms and therapeut |
| P2RX7-PANX1 Channel Blockade for Neuroinflammatory Cascade I | 0.105 | neurodegeneration | Neuroinflammation Biomarker Panel for Ea |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.605
neurodegeneration | 2026-04-11 | 0 hypotheses
neurodegeneration | 2026-04-04 | 15 hypotheses Top: 0.814
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.741
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.732
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| P2RX7 variant rs1718119 association with glucose homeostasis in Botnia | exploratory | type 2 diabetes | 0.900 | 0.00 | human patients | proposed | N/A |
| P2rx7 genetic deletion in PS19 tauopathy mice | validation | Alzheimer's disease/tauopathy | 0.900 | 0.00 | PS19 tauopathy mice | proposed | N/A |
| P2rx7 congenic mouse model insulin tolerance testing | validation | insulin resistance | 0.900 | 0.00 | congenic mice (C57BL6 P2rx7 al | proposed | N/A |
| P2rx7 congenic mouse model glucose tolerance testing | validation | glucose intolerance | 0.900 | 0.00 | congenic mice (C57BL6 P2rx7 al | proposed | N/A |
| Single-cell RNA sequencing of mouse brains | exploratory | Alzheimer's disease/tauopathy | 0.900 | 0.00 | PS19 mouse brain tissue | proposed | N/A |
| Cell type-specific P2rx7 deletion in microglia vs astrocytes | validation | Alzheimer's disease/tauopathy | 0.850 | 0.00 | PS19 mice with cell type-speci | proposed | N/A |
| Brain-derived extracellular vesicles proteome analysis | exploratory | Alzheimer's disease/tauopathy | 0.850 | 0.00 | Brain-derived extracellular ve | proposed | N/A |
| BDEV injection and recipient microglial transcriptome analysis | validation | Alzheimer's disease/tauopathy | 0.800 | 0.00 | Recipient mice injected with B | proposed | N/A |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| No papers found | ||||
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 1.00 · 2026-04-26
closed · Rounds: 4 · Score: 1.00 · 2026-04-20
closed · Rounds: 4 · Score: 0.90 · 2026-04-12
closed · Rounds: 4 · Score: 0.69 · 2026-04-12
closed · Rounds: 7 · Score: 0.91 · 2026-04-10
closed · Rounds: 4 · Score: 0.95 · 2026-04-10
closed · Rounds: 3 · Score: 0.95 · 2026-04-04
Hypotheses and analyses mentioning P2RX7 in their description or question text
No additional research found